Compare Stocks: DRTS, TFX, HAE, and LIVN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DRTS Alpha Tau Medical	$14.77 +1.7%	$13.97	$3.43 ▼ $15.79	$1.37B	1.2	614,955 shs	467,024 shs
HAE Haemonetics	$106.14 -0.6%	$96.13	$47.31 ▼ $110.45	$4.94B	0.54	582,242 shs	416,797 shs
LIVN LivaNova	$75.44 -2.2%	$79.65	$48.82 ▼ $85.76	$4.32B	0.87	598,606 shs	1.06 million shs
TFX Teleflex	$120.15 -1.3%	$134.25	$100.18 ▼ $145.00	$5.29B	0.82	681,988 shs	869,638 shs

10 Best Stocks to Own - Fall 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Fall 2026, despite the economic uncertainty rattling markets right now. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DRTS Alpha Tau Medical	+1.72%	-4.65%	+0.48%	+35.75%	+263.79%
HAE Haemonetics	-0.81%	-1.69%	-2.04%	+37.24%	+109.58%
LIVN LivaNova	-2.23%	-3.02%	-5.00%	-9.52%	+41.72%
TFX Teleflex	-1.41%	-4.18%	-14.22%	-7.27%	-2.52%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DRTS Alpha Tau Medical	$14.77 +1.7%	$13.97	$3.43 ▼ $15.79	$1.37B	1.2	614,955 shs	467,024 shs
HAE Haemonetics	$106.14 -0.6%	$96.13	$47.31 ▼ $110.45	$4.94B	0.54	582,242 shs	416,797 shs
LIVN LivaNova	$75.44 -2.2%	$79.65	$48.82 ▼ $85.76	$4.32B	0.87	598,606 shs	1.06 million shs
TFX Teleflex	$120.15 -1.3%	$134.25	$100.18 ▼ $145.00	$5.29B	0.82	681,988 shs	869,638 shs

10 Best Stocks to Own - Fall 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DRTS Alpha Tau Medical	+1.72%	-4.65%	+0.48%	+35.75%	+263.79%
HAE Haemonetics	-0.81%	-1.69%	-2.04%	+37.24%	+109.58%
LIVN LivaNova	-2.23%	-3.02%	-5.00%	-9.52%	+41.72%
TFX Teleflex	-1.41%	-4.18%	-14.22%	-7.27%	-2.52%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DRTS Alpha Tau Medical	2.38	Hold	$15.40	4.27% Upside
HAE Haemonetics	2.73	Moderate Buy	$99.78	-5.99% Downside
LIVN LivaNova	2.55	Moderate Buy	$84.13	11.51% Upside
TFX Teleflex	2.42	Hold	$152.90	27.25% Upside

Current Analyst Ratings Breakdown

Latest DRTS, TFX, HAE, and LIVN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/21/2026	TFX Teleflex	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D)
9/3/2026	HAE Haemonetics	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$105.00 ➝ $125.00
9/3/2026	DRTS Alpha Tau Medical	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$17.00 ➝ $30.00
9/2/2026	LIVN LivaNova	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$87.00 ➝ $90.00
9/1/2026	DRTS Alpha Tau Medical	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
8/25/2026	TFX Teleflex	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$159.00 ➝ $170.00
8/21/2026	HAE Haemonetics	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$96.00 ➝ $119.00
8/19/2026	HAE Haemonetics	Barrington Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$95.00 ➝ $118.00
8/19/2026	LIVN LivaNova	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/18/2026	LIVN LivaNova	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C) ➝ Hold (C+)
8/18/2026	HAE Haemonetics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$96.00 ➝ $110.00

(Data available from 9/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DRTS Alpha Tau Medical	N/A	N/A	N/A	N/A	$0.88 per share	N/A
HAE Haemonetics	$1.33B	3.62	$7.41 per share	14.32	$17.14 per share	6.19
LIVN LivaNova	$1.39B	2.99	$4.65 per share	16.23	$21.98 per share	3.43
TFX Teleflex	$1.99B	2.55	$10.77 per share	11.16	$70.71 per share	1.70

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DRTS Alpha Tau Medical	-$42.63M	-$1.04	N/A	N/A	N/A	N/A	-138.12%	-81.68%	11/19/2026 (Estimated)
HAE Haemonetics	$97.31M	$2.04	52.03	18.52	2.17	7.12%	27.55%	9.65%	11/5/2026 (Estimated)
LIVN LivaNova	-$242.47M	$3.38	22.32	18.13	N/A	12.82%	16.35%	7.76%	11/4/2026 (Estimated)
TFX Teleflex	-$905.64M	-$23.29	N/A	10.95	0.83	-39.67%	11.93%	5.44%	11/5/2026 (Estimated)

Latest DRTS, TFX, HAE, and LIVN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/10/2026	Q2 2026	DRTS Alpha Tau Medical	-$0.1409	-$0.50	-$0.3591	-$0.50	$0.14 million	N/A
8/6/2026	Q1 2027	HAE Haemonetics	$1.08	$1.14	+$0.06	$0.72	$327.86 million	$339.38 million
8/6/2026	Q2 2026	LIVN LivaNova	$1.09	$1.26	+$0.17	$1.93	$380.50 million	$390.59 million
8/6/2026	Q2 2026	TFX Teleflex	$1.28	$1.76	+$0.48	$2.28	$559.59 million	$570.33 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
DRTS Alpha Tau Medical	N/A	N/A	N/A	N/A	N/A
HAE Haemonetics	N/A	N/A	N/A	N/A	N/A
LIVN LivaNova	N/A	N/A	N/A	N/A	N/A
TFX Teleflex	$1.36	1.13%	N/A	N/A	N/A

Latest DRTS, TFX, HAE, and LIVN Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
8/4/2026	TFX Teleflex	quarterly	$0.34	0.99%	8/14/2026	8/14/2026	9/30/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DRTS Alpha Tau Medical	0.15	11.09	7.79
HAE Haemonetics	1.40	3.08	1.91
LIVN LivaNova	0.22	1.45	1.21
TFX Teleflex	0.94	2.60	2.12

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DRTS Alpha Tau Medical	2.65%
HAE Haemonetics	99.67%
LIVN LivaNova	97.64%
TFX Teleflex	95.62%

Insider Ownership

Company	Insider Ownership
DRTS Alpha Tau Medical	39.50%
HAE Haemonetics	2.07%
LIVN LivaNova	0.35%
TFX Teleflex	0.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DRTS Alpha Tau Medical	121	90.33 million	54.65 million	No Data
HAE Haemonetics	3,009	45.50 million	44.56 million	Optionable
LIVN LivaNova	3,300	55.09 million	54.90 million	Optionable
TFX Teleflex	15,500	42.37 million	42.08 million	Optionable

DRTS, TFX, HAE, and LIVN Headlines

Recent News About These Companies

Teleflex stock heads into the open after a 0.94 percent drop

September 23 at 11:23 PM | ad-hoc-news.deA

Teleflex stock holds near USD 125 as target cuts sharpen the debate

September 23 at 1:22 PM | ad-hoc-news.deA

Teleflex stock heads into the open after September 21 gains

September 22 at 5:20 PM | ad-hoc-news.deA

Corient Private Wealth LP Has $2.92 Million Holdings in Teleflex Incorporated $TFX

September 22 at 3:27 AM | marketbeat.com

Bank of America Corp DE Invests $61.16 Million in Teleflex Incorporated $TFX

September 21, 2026 | marketbeat.com

Teleflex (TFX) Adds A Board Veteran, Is The 19% Undervalued View Enough?

September 20, 2026 | finance.yahoo.com

Here's Why Teleflex (TFX) is a Strong Value Stock

September 16, 2026 | zacks.com

5 Low P/B Stocks That Offer Attractive Value and Growth

September 15, 2026 | zacks.com

VIRGINIA RETIREMENT SYSTEMS ET Al Acquires New Shares in Teleflex Incorporated $TFX

September 14, 2026 | marketbeat.com

Teleflex Incorporated $TFX Shares Sold by Amundi

September 14, 2026 | marketbeat.com

Teleflex Incorporated $TFX Stake Lowered by California State Teachers Retirement System

September 14, 2026 | marketbeat.com

TFX vs. PEN: Which Stock Is the Better Value Option?

September 11, 2026 | zacks.com

Teleflex Incorporated (NYSE:TFX) Given Consensus Recommendation of "Hold" by Brokerages

September 11, 2026 | marketbeat.com

Teleflex stock heads into the open after a 3.3 percent weekly gain

September 9, 2026 | ad-hoc-news.deA

Surgical Equipment & Consumables - Specialty Stocks Q2 Earnings Review: Teleflex (NYSE:TFX) Shines

September 9, 2026 | finance.yahoo.com

Teleflex Incorporated Announces Appointment of Sean M. Salmon to Board of Directors and to the Growth and Operating Committee, Effective September 8, 2026

September 8, 2026 | marketscreener.comM

Medtronic veteran joins Teleflex’s board

September 8, 2026 | massdevice.com

Teleflex Appoints Veteran Medical Technology Executive Sean M. Salmon to Teleflex Board of Directors

September 8, 2026 | finance.yahoo.com

Public Employees Retirement System of Ohio Makes New Investment in Teleflex Incorporated $TFX

September 8, 2026 | marketbeat.com

Teleflex Inc. stock gains attention as new Dynetic-35 stent debuts at CIRSE 2026

September 6, 2026 | ad-hoc-news.deA

Teleflex Showcases Dynetic-35 Balloon-Expandable Cobalt Chromium Stent System At Cirse 2026

September 5, 2026 | marketscreener.comM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

DRTS, TFX, HAE, and LIVN Company Descriptions

Alpha Tau Medical NASDAQ:DRTS

$14.77 +0.25 (+1.72%)

Closing price 09/24/2026 04:00 PM Eastern

Extended Trading

$15.00 +0.23 (+1.55%)

As of 09/24/2026 07:58 PM Eastern

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.

Haemonetics NYSE:HAE

$106.14 -0.68 (-0.64%)

Closing price 09/24/2026 03:59 PM Eastern

Extended Trading

$106.03 -0.11 (-0.10%)

As of 09/24/2026 07:30 PM Eastern

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.

LivaNova NASDAQ:LIVN

$75.44 -1.72 (-2.23%)

Closing price 09/24/2026 04:00 PM Eastern

Extended Trading

$75.46 +0.02 (+0.02%)

As of 09/24/2026 07:30 PM Eastern

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, markets, and sells VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve; difficult-to-treat depression and drug-resistant epilepsy devices. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products. It serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. The company sells its products through direct sales representatives and independent distributors. LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom.

Teleflex NYSE:TFX

$120.15 -1.60 (-1.31%)

Closing price 09/24/2026 03:59 PM Eastern

Extended Trading

$122.57 +2.42 (+2.01%)

As of 09/24/2026 07:45 PM Eastern

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. It also offers interventional products, which consists of various coronary catheters, structural heart support devices, and peripheral intervention and mechanical circulatory support platform that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded pumps and catheters, Guideline, Turnpike, and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. The company provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. It also offers interventional urology products comprising the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings; urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management services. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. Teleflex Incorporated was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DRTS, TFX, HAE, and LIVN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DRTS, TFX, HAE, and LIVN Earnings

Compare Dividends

Latest DRTS, TFX, HAE, and LIVN Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DRTS, TFX, HAE, and LIVN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

DRTS, TFX, HAE, and LIVN Company Descriptions

Alpha Tau Medical NASDAQ:DRTS

Haemonetics NYSE:HAE

LivaNova NASDAQ:LIVN

Teleflex NYSE:TFX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools